Skip to Content
MilliporeSigma
  • Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.

Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.

The Journal of pharmacology and experimental therapeutics (2014-06-21)
Yasuo Uchida, Kentaro Wakayama, Sumio Ohtsuki, Masato Chiba, Tomoyuki Ohe, Yasuyuki Ishii, Tetsuya Terasaki
ABSTRACT

The aim of this study was to investigate whether in vivo drug distribution in brain in monkeys can be reconstructed by integrating four factors: protein expression levels of P-glycoprotein (P-gp)/multidrug resistance protein 1 at the blood-brain barrier (BBB), in vitro transport activity per P-gp molecule, and unbound drug fractions in plasma and brain. For five P-gp substrates (indinavir, quinidine, loperamide, paclitaxel, and verapamil) and one nonsubstrate (diazepam), in vitro P-gp transport activities were determined by measuring transcellular transport across monolayers of cynomolgus monkey P-gp-transfected LLC-PK1 and parental cells. In vivo P-gp functions at the BBB were reconstructed from in vitro P-gp transport activities and P-gp expression levels in transfected cells and cynomolgus brain microvessels. Brain-to-plasma concentration ratios (Kp,brain) were reconstructed by integrating the reconstructed in vivo P-gp functions with drug unbound fractions in plasma and brain. For all compounds, the reconstructed Kp,brain values were within a 3-fold range of observed values, as determined by constant intravenous infusion in adult cynomolgus monkeys. Among four factors, plasma unbound fraction was the most sensitive factor to species differences in Kp,brain between monkeys and mice. Unbound brain-to-plasma concentration ratios (Kp,uu,brain) were reconstructed as the reciprocal of the reconstructed in vivo P-gp functions, and the reconstructed Kp,uu,brain values were within a 3-fold range of in vivo values, which were estimated from observed Kp,brain and unbound fractions. This study experimentally demonstrates that brain distributions of P-gp substrates and nonsubstrate can be reconstructed on the basis of pharmacoproteomic concept in monkeys, which serve as a robust model of drug distribution in human brain.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Loperamide hydrochloride
Sigma-Aldrich
(±)-Verapamil hydrochloride, ≥99% (titration), powder
Supelco
(±)-Verapamil hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Loperamide hydrochloride, United States Pharmacopeia (USP) Reference Standard
Loperamide hydrochloride, European Pharmacopoeia (EP) Reference Standard
Indinavir, European Pharmacopoeia (EP) Reference Standard
Supelco
Loperamide hydrochloride, VETRANAL®, analytical standard
Supelco
Loperamide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Quinidine, crystallized, ≥98.0% (dried material, NT)
Sigma-Aldrich
Diazepam
Sigma-Aldrich
Quinidine, anhydrous
Supelco
Diazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Verapamil hydrochloride, European Pharmacopoeia (EP) Reference Standard
Diazepam, European Pharmacopoeia (EP) Reference Standard
USP
Verapamil hydrochloride, United States Pharmacopeia (USP) Reference Standard